Description

The NQO1, NQO2 Knockout HEK293T Cell Line is a CRISPR/Cas9-edited knockout cell line designed for investigating the roles of NAD(P)H:quinone oxidoreductase 1 and 2 in cellular detoxification and antioxidant responses. This cell line, derived from the HEK293T host, carries targeted disruptions in both the NQO1 and NQO2 genes, providing a dual-loss-of-function model. The use of CRISPR/Cas9 technology ensures effective ablation of gene function, enabling researchers to dissect the individual and combined contributions of these enzymes to quinone metabolism and stress signaling pathways.

The HEK293T host cell line is a well-characterized human embryonic kidney epithelial cell line that stably expresses the SV40 large T antigen, derived from the original HEK293 strain. Its epithelial origin, rapid proliferation, and high transfection competency make it an ideal platform for gene editing and functional studies. HEK293T cells retain many features of kidney epithelial cells, including responsiveness to oxidative stress and xenobiotic stimuli, providing a physiologically relevant background for examining the roles of NQO1 and NQO2 in antioxidant defense and detoxification.

NQO1 and NQO2 are flavin-dependent quinone reductases that catalyze the obligate two-electron reduction of quinones to hydroquinones, thereby preventing semiquinone radical formation. Their expression is transcriptionally regulated by NFE2L2 (NRF2), which is sequestered by KEAP1 and targeted for degradation by the CUL3 ubiquitin ligase complex. Under oxidative stress, NRF2 is released, dimerizes with MAF proteins, and binds antioxidant response elements (AREs) to induce NQO1, NQO2, HMOX1, and other cytoprotective targets. NQO1 also physically interacts with and stabilizes the tumor suppressor p53 (TP53), protecting it from proteasomal degradation and enhancing its transcriptional activity. NQO2 can utilize NRH or melatonin as co-substrates and is implicated in melatonin-binding and circadian modulation.

In HEK293T cells expressing functional NRF2, KEAP1, and p53, the simultaneous knockout of NQO1 and NQO2 provides a unique platform to study NRF2-ARE signaling and p53 crosstalk. Disruption of these major NRF2 effectors separates transcriptional outcomes from enzymatic detoxification. Loss of NQO1 destabilizes p53, enabling detailed analysis of p53-dependent responses to genotoxic and oxidative stress. The epithelial nature of HEK293T cells also makes this model relevant to renal and epithelial cancers where NQO1 and NQO2 are often dysregulated.

This knockout cell line is suited for investigating NRF2 pathway dynamics, quinone-mediated redox cycling, and p53 regulation. Researchers can use Western blotting and RT-qPCR for expression analysis, and enzymatic activity assays with menadione or other quinones to measure residual reductase function. Oxidative stress challenges and cell viability assays reveal the cytoprotective roles of NQO1/NQO2. The line supports p53 stabilization assays and high-content screens for compounds that bypass NQO1-dependent p53 protection, facilitating drug discovery and toxicology studies. For further details, contact Ascent Research.